


# Pharmaceuticals Industry Council

*Local priority – Global partner*



## The Value of Industry Sponsored Clinical Research in Australia- The PIC-RDTF Benchmarking Survey

**Dr Melissa Grady**  
**Head of Clinical Research AstraZeneca**  
**Co-Chair of PIC-RDTF**

*Prepared on Behalf of the Pharmaceuticals Industry Council by the Research and Development Taskforce July 2009*



# **PIC-RDTF strategic objectives**

- **2002 - Pharmaceutical Industry Action Agenda (PIAA)**
  - Double Australia's share of the global pharmaceuticals industry by 2012 through the collaborative efforts of the industry, government and research
- **2004 - PIAA RDTF**
  - globally competitive : Ensure regulatory and clinical trial environment supports industry's needs
  - Further streamline ethics approval processes in conducting health and medical research including clinical trials
  - Export of services (CRO)
  - Gaps in preclinical service capability

# PIC – RDTF Mandate

**Attract Clinical Trials**

**Quality**

**Timeliness**

**Value (Cost)**

**Capacity**



# Pharmaceutical Industry Strategy Group Report

[www.innovation.gov.au/pisg](http://www.innovation.gov.au/pisg)

April 2008 - announced by Minister Carr  
September 2008 – Interim Report  
December 2008 - Final Report to Minister  
January 2009 – Final Report released

**Strategy to increase Investment in Clinical Trials**



## Data Required to Drive Discussion and Action

- Numerous stakeholders (eg., during PISG process) noted anecdotal evidence of changing competitive landscape and inferred value of research
- Need to determine
  - Value of research – *what do Investigators think?*
  - Exactly what is our benchmark – *just how competitive are we?*
- In line with RDTF mandate to ensure the environment of industry remains competitive through gathering data on key issues
  - Benchmarking data needed, and needs to be ongoing



## **Benchmarking Survey of Industry Sponsored Clinical Research in Australia in 2008**

- **Commissioned by PIC RDTF [for activities undertaken in 2008]**
- **Compiled by the Pharmaceuticals Industry Council Secretariat**
- **Results (slides) available at [www.pharmacouncil.com.au/resources](http://www.pharmacouncil.com.au/resources)**
- **Survey instrument available on request**

-----

- **23 multinational** and **10 Australian** corporations responded
- **\$285 million** reported in expenditure on clinical research
- **1431 trials** reported



## Threats and Challenges

# INCREASING GLOBAL COMPETITION FOR INVESTMENT

## ■ **Timeliness**

- faster study start up and patient recruitment

## ■ **Capacity**

- better patient referral patterns; greater recruitment reliability

## ■ **Value**

- keeping costs competitive and improving efficiency


## ■ **Quality**

- staff accreditation; innovate (translational medicine capability)
-



## 2009 PIC RDTF Benchmarking Data – Multinational Corporations\*


### Type of Activity



**Global trials and significant local researcher-led activity**



## 2009 PIC RDTF Benchmarking Data – Composite Data\*



- **1431** trials were reported by 33 companies
- Majority of these were conducted by multinational corporations